YCYaling Cao

Yaling Cao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yaling Cao has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Unveiling the underestimated prevalence of HIV, HBV and TB triple infection in Asia, South America, and Africa: a systematic review and meta-analysis

    by Yinkang Mo, Zihao Fan, Yaling Cao, Ling Xu, Xiangying Zhang, Feng Ren

    Background: Human immunodeficiency virus (HIV) is a genus of retroviruses that targets immune cells and may eventually cause immune-deficiency illness. Triple infection of HIV/hepatitis B virus (HBV) /tuberculosis (TB) leads to a worse prognosis than mono-infection. We aimed to unveil the pooled estimation of HIV/HBV/TB co-infection prevalence in Asia, South America, and Africa. Methods: A systematic literature search in PubMed, Embase, and the Cochrane Library was performed for studies of the prevalence of HIV/HBV/TB triple infection published from January 1, 1990, to March 31, 2024. The Freeman–Tukey random effects model was used to calculate the pooled prevalence. Results: We included 7 studies with in total 6401 participants and 259 triple infection cases. The pooled triple infection rate in the enrolled population was 4.4% (259/6401; 95% CI 2.2%-7.3%). The results of the subgroup analysis showed that the prevalence of triple infection was significantly higher in the South America (82/950, 8.6%; 95% CI 6.8%-10.4%), in men (86/1817, 3.4%; 95% CI 0.7%-7.8%) and patients receiving antiretroviral treatment (125/1611, 7.4%; 95% CI 5.8%–9.2%). However, no significant difference in the triple infection rate was observed among individuals initially diagnosed with HIV or TB. Conclusions: This meta-analysis suggests that the prevalence of HIV/HBV/TB triple infection in the regions studied is underestimated, and we should focus more effort on improving novel strategies for identifying triple infection of HIV/HBV/TB. However, additional studies are required to be incorporated in future analyses to provide a pooled estimate of the global pooled prevalence. Clinical trial: Not applicable.

  • Open Access

    Diagnostic Efficacy of Serological Antibody Detection Tests for Hepatitis Delta Virus: A Systematic Review and Meta-Analysis

    by Zhenzhen Pan, Sisi Chen, Ling Xu, Yao Gao, Yaling Cao, Zihao Fan, Yuan Tian, Xiangying Zhang, Zhongping Duan, Feng Ren

    Background and Aims Coinfection of hepatitis delta virus (HDV) with hepatitis B virus (HBV) causes the most severe form of viral hepatitis, and the global prevalence of HDV infection is underestimated. Although serological testing of anti-HDV antibodies is widely used in the diagnosis of HDV, its diagnostic efficacy remains unclear. This study aimed to evaluate the diagnostic efficacy of HDV serological tests, the results of which may assist in the diagnosis of HDV. Methods Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were followed. The PubMed, Web of Science and Cochrane Library databases were searched from the beginning to 31 May 2023. Study quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. STATA SE was used for the meta-analysis of the sensitivity, specificity, positive likelihood ratio and negative likelihood ratio. Results Among a total of 1376 initially identified studies, only 12 articles met the final inclusion criteria. The pooled sensitivity and specificity were 1.00 (95% CI: 0.00–1.00) and 0.71 (95% CI: 0.50–0.78) for HDV total antibodies, 0.96 (95% CI: 0.83–0.99) and 0.98 (95% CI: 0.82–1.00) for anti-HDV IgM and 0.95 (95% CI: 0.86–0.98) and 0.96 (95% CI: 0.67–1.00) for anti-HDV IgG. The pooled sensitivity and specificity for HDV serological tests were 0.99 (95% CI: 0.96–1.00) and 0.90 (95% CI: 0.79–0.96). Conclusions This meta-analysis suggests that serological tests have high diagnostic performance in detecting antibodies against HDV, especially in HDV IgM and IgG. However, this conclusion is based on studies of a limited number and quality, and the development of new diagnostic tools with higher precision and reliability is still necessary.


  • Open Access

    CRISPR/Cas13-assisted carbapenem-resistant Klebsiella pneumoniae detection

    by Yaling Cao, Yuan Tian, Jing Huang, Ling Xu, Zihao Fan, Zhenzhen Pan, Sisi Chen, Yao Gao, Linlin Wei, Sujun Zheng, et al.


  • Open Access

    CRISPR/Cas13a-assisted rapid and portable HBV DNA detection for low-level viremia patients

    by Yuan Tian, Zihao Fan, Ling Xu, Yaling Cao, Sisi Chen, Zhenzhen Pan, Yao Gao, Hao Li, Sujun Zheng, Yingmin Ma, et al.

    The WHO declared to eliminate hepatitis B virus (HBV) by 2030. However, an increasing number of patients are presenting with low-level viremia (LLV) with the widespread use of antiviral medications...


  • Open Access

    Digital Droplet PCR for Detection and Quantitation of Hepatitis Delta Virus

    by Ling Xu, Xiangying Zhang, Yaling Cao, Zihao Fan, Yuan Tian, Huanbin Zou, Yingmin Ma, Zhongping Duan, Feng Ren

    INTRODUCTION: Hepatitis delta virus (HDV) far exceeds our expected level. There remains a lack of reliable quantitative assays for HDV RNA detection. We sought to develop a new method based on digital droplet polymerase chain reaction (ddPCR) for HDV quantitative detection. METHODS: With plasmid (pMD19T) containing HDV full genome, we determined the method for ddPCR-based HDV RNA quantification. To compare various assays for HDV detection, 30 cases diagnosed with hepatitis D and 14 controls were examined using enzyme-linked immunosorbent assay, reverse-transcriptase PCR (RT-PCR), and ddPCR. A total of 728 hepatitis B virus–related patients, including 182 patients with chronic hepatitis B, 182 with liver cirrhosis, 182 with hepatocellular carcinoma, and 182 with liver failure, were screened for HDV infection. RESULTS: The detection limit of ddPCR for HDV is significantly low, with lower limit of detection and lower limit of quantitation of 0.29 IU/mL (95% confidence interval: 1.93 × 10−3–1.22 IU/mL) and 8.76 IU/mL (95% confidence interval: 1.83–1.03 × 106 IU/mL), respectively. Among the 44 samples, the enzyme-linked immunosorbent assay detected 30 cases positive, ddPCR reported 24 samples, and RT-PCR reported 10 samples positive for HDV RNA. Moreover, the positive rates of anti-HDV were 1.1%, 3.3%, 2.7%, and 7.1% in patients with chronic hepatitis B, liver cirrhosis, hepatocellular carcinoma, and liver failure, respectively; the detection rates of RT-PCR in HDV RNA were 0%, 16.67%, 15.4%, and 20%, respectively. However, the detection rates of ddPCR were 0%, 33.33%, 30.77%, and 60%, respectively. DISCUSSION: We establish a high sensitivity and specificity quantitative HDV RNA detection method based on ddPCR. Hepatitis B virus–related end-stage liver diseases, especially liver failure, are associated with a remarkably high rate of HDV infection.


  • Open Access

    CRISPR/Cas13-assisted hepatitis B virus covalently closed circular DNA detection

    by Xiangying Zhang, Yuan Tian, Ling Xu, Zihao Fan, Yaling Cao, Yingmin Ma, Hao Li, Feng Ren

    Background and aims: The formation of an intranuclear pool of covalently closed circular DNA (cccDNA) in the liver is the main cause of persistent hepatitis B virus (HBV) infection. Here, we established highly sensitive and specific methods to detect cccDNA based on CRISPR-Cas13a technology. Methods: We used plasmid-safe ATP-dependent DNase (PSAD) enzymes and HindIII to digest loose circle rcDNA and double-stranded linear DNA, amplify specific HBV cccDNA fragments by rolling circle amplification (RCA) and PCR, and detect the target gene using CRISPR-Cas13a technology. The CRISPR-Cas13a-based assay for the detection of cccDNA was further clinically validated using HBV-related liver tissues, plasma, whole blood and peripheral blood mononuclear cells (PBMCs). Results: Based on the sample pretreatment step, the amplification step and the detection step, we established a new CRISPR-Cas13a-based assay for the detection of cccDNA. After the amplification of RCA and PCR, 1 copy/μl HBV cccDNA could be detected by CRISPR/Cas13-assisted fluorescence readout. We used ddPCR, qPCR, RCA-qPCR, PCR-CRISPR and RCA-PCR-CRISPR methods to detect 20, 4, 18, 14 and 29 positive samples in liver tissue samples from 40 HBV-related patients, respectively. HBV cccDNA was almost completely undetected in the 20 blood samples of HBV patients (including plasma, whole blood and PBMCs) by the above 5 methods. Conclusions: We developed a novel CRISPR-based assay for the highly sensitive and specific detection of HBV cccDNA, presenting a promising alternative for accurate detection of HBV infection, antiviral therapy evaluation and treatment guidance.